Interleukin (IL)−6 inhibition has been approved for the treatment of rheumatoid arthritis, systemic juvenile arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and, in some countries, Castleman’s disease. IL-6 has also been implicated in several non-rheumatoid arthritis inflammatory and immune conditions such as systemic sclerosis, vasculitides, systemic lupus erythematous, and psoriatic arthritis. In orphan diseases, such as systemic sclerosis, which are associated with significant morbidity and mortality and for which there are no approved treatments, IL-6 inhibition may offer a promising treatment strategy. It is also becoming clear that IL-6 may have an important role not only in inflammatory and immune diseases but also in non-immune mediated diseases such as endogenous depression and depression associated with chronic inflammatory conditions. Several studies have explored the effect of IL-6 pathway inhibition in Crohn’s disease and adult-onset Still’s disease, suggesting that IL-6 may be important in their pathogenesis.

中文翻译：

---

IL-6：免疫力超越

白介素（IL）-6抑制剂已被批准用于治疗类风湿性关节炎，系统性幼年关节炎，多关节性幼年特发性关节炎，巨细胞性动脉炎，在某些国家还包括Castleman病。IL-6还与几种非类风湿关节炎的炎症和免疫疾病有关，例如全身性硬化症，血管炎，全身性红斑狼疮和牛皮癣性关节炎。在孤儿疾病（例如全身性硬化症）中，其与高发病率和高死亡率相关，并且尚无批准的治疗方法，IL-6抑制可能提供有希望的治疗策略。同样清楚的是，IL-6不仅在炎症和免疫疾病中而且在非免疫介导的疾病例如内源性抑郁症和与慢性炎症性疾病相关的抑郁症中也可能起重要作用。几项研究探索了IL-6途径抑制在克罗恩病和成年性Still病中的作用，表明IL-6在其发病机理中可能很重要。